Indoco Remedies Q1 FY27: Revenue Grows 8.2% to ₹4,662 Million; Baddi Unit III Gets EU-GMP
Indoco Remedies reported Q1 FY27 consolidated revenue of ₹4,662 million, up 8.2% YoY. Standalone revenue grew 5.8% to ₹4,081 million. EBITDA margin was 10.3% standalone. Key facilities received EU-GMP certification and cleared USFDA inspection. Domestic formulations revenue was ₹2,040 million, and API business surged 42% to ₹522 million.
The results show positive growth and operational improvements, including regulatory approvals, which are significant for the company's future prospects. However, the impact is not categorized as HIGH due to the absence of major new product launches or blockbuster financial figures.
The company reported revenue growth, improved margins, and successful regulatory audits, indicating positive operational performance and strategic progress.
Indoco Remedies Limited announced its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The company reported a standalone operational revenue growth of 5.8% year-on-year, reaching ₹4,081 million. Consolidated revenue increased by 8.2% year-on-year to ₹4,662 million.
Standalone EBITDA expanded to ₹422 million, with an EBITDA margin of 10.3%. This performance was attributed to strong execution in domestic formulations, regulated international markets, and the API platform.
On the regulatory front, Indoco's Baddi Unit I successfully completed a Malta Medicines Authority audit. Baddi Unit III facility received EU-GMP certification from the German Health Authority, Berlin, and Goa Plant I also cleared the Malta Medicines Authority audit, securing EU-GMP certification. Additionally, the Indoco Stability Center (IAS) in Aurangabad completed a USFDA pre-approval inspection with zero observations.
The domestic formulations business recorded revenues of ₹2,040 million. Indoco maintained its position in the Indian pharma market at 33rd rank (IQVIA MAT June '26), and 20th in prescription volume (MAT May '26). The top 5 flagship brands now contribute 42% to the domestic portfolio, with Cyclopam showing 44% growth since 2022 and Febrex Plus stabilizing at ₹118 crores. Midsized brands showed an aggregate growth of 86%.
International formulations contributed 35% of Q1 FY27 revenue at ₹1,451 million. The active pharmaceuticals ingredients (API) business surged by 42% year-on-year to ₹522 million. The company is focused on scaling midsized brands, deepening specialty prescription share, and expanding its chronic footprint in India, while leveraging R&D, CRO, and API capabilities for high-value filings internationally.
The company reported consolidated EBITDA to net sales of 8.8% (₹410 million) for the quarter. Revenues from regulated markets grew by 19.3% to ₹1,133 million, with the US business growing by 62.2% to ₹459 million. The API business grew by 42.4% to ₹521 million. The company is working towards reducing its debt, with a target to repay ₹110 crores this year and another ₹150 crores next year. Management is focused on cost optimization and operational excellence to improve margins.
What to do with a filing like this
Indoco Remedies Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Indoco Remedies Limited. Read the original for the full detail.